Study Suggests Novartis’ LCZ696 May Transform Heart Failure Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ experimental LCZ696 showed superiority over ACE inhibitor enalapril on several key endpoints in the largest heart failure study ever done - boosting prospects the two-in-one pill will be a huge success.